Notable Analyst Upgrades, Downgrades and Comments
Earn exceptional risk-adjusted returns with Sumfolio.com's quarterly value stock picks!
Duoyuan Printing, Inc. (NYSE:DYP), Mednax, Inc. (NYSE:MD), and OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) are three notable analyst upgrades, downgrades and comments for February 8, 2010.
Duoyuan is Printing Profits for Shareholders
Duoyuan Printing, Inc. (DYP, Free Analysis), an offset printing equipment supplier in China, could see significant upside during its second quarter, according to at least one analyst. Roth Capital predicted that the company’s second quarter results would surpass estimates, and noted that it continues to see several growth drivers for the business.
Currently, Duoyuan Printing trades with a trailing 12-month price-earnings ratio of approximately 6.44x with a projected 5-year forward growth rate of over 17%. The company expects to report its second quarter earnings before the market opens at 7:00 a.m. Eastern Time on February 11, 2010.
Receive Free DYP Analysis by E-Mail
Mednax’s Guidance Appears Overly Conservative
Mednax, Inc. (MD, Free Analysis), a provider of physician services, saw its shares sell off nearly 10% after offering lackluster first quarter guidance. The company’s fourth quarter results climbed 23% to $1.00, which beat analyst consensus by $0.02 per share. However, at least one analyst believes that the guidance was overly conservative and shares are now oversold.
Kaufman Bros. believes that the weakness in Mednax’s shares was caused by the company’s first quarter guidance, which it views as conservative. As a result, the analyst believes shares now undervalued and maintains a Buy rating. Meanwhile, Citigroup also upgraded the firm after its earnings report to a Buy from a Hold.
Receive Free MD Analysis by E-Mail
OncoGenex is the Best Value Play in Oncology
OncoGenex Pharmaceuticals Inc. (OGXI, Free Analysis), a biopharmaceutical company focusing on cancer therapies, saw its shares surge more than 5% after positive comments from one analyst. Another analyst cautioned in January that a lack of near-term catalysts could continue to pressure shares, but maintained its Outperform rating on the stock.
Thomas Weisel believes that OncoGenex is the best clinical data play on the prostate cancer sector and the best value play in the oncology space, after a meeting with the company’s management. As a result, the firm maintains its Overweight rating on the stock. As a result, shares rallied more than 5% during the session.
Receive Free OGXI Analysis by E-Mail
Join Now, It's FREE!
Membership Benefits
- Memebers' Only Newsletter - Our premium members' only newsletter contains unique stock picks and market commentary not available on-site.
- Unlimited Traders' Forum Access - Members receive access to members' only portions of the forum that aren't viewable by the public, along with the ability to post on our forum.
- Free Educational Resources - Members have exclusive access to our free educational materials, as well as discounted prices on our premium educational materials.
